Virtu Financial LLC Takes $654,000 Position in Monopar Therapeutics Inc. $MNPR

Virtu Financial LLC acquired a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 10,009 shares of the company’s stock, valued at approximately $654,000. Virtu Financial LLC owned about 0.15% of Monopar Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP purchased a new position in Monopar Therapeutics in the third quarter valued at about $18,904,000. Siren L.L.C. purchased a new stake in shares of Monopar Therapeutics during the fourth quarter valued at about $13,863,000. Deerfield Management Company L.P. bought a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at about $13,048,000. RA Capital Management L.P. boosted its holdings in shares of Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after buying an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC purchased a new position in shares of Monopar Therapeutics in the 3rd quarter worth approximately $12,496,000. Institutional investors own 1.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MNPR. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a report on Monday, March 30th. HC Wainwright reaffirmed a “buy” rating on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Finally, BTIG Research reiterated a “buy” rating and set a $104.00 price objective on shares of Monopar Therapeutics in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics presently has an average rating of “Buy” and an average target price of $107.91.

Monopar Therapeutics Stock Up 1.8%

MNPR stock opened at $68.66 on Tuesday. The stock has a market capitalization of $460.02 million, a PE ratio of -36.14 and a beta of 1.52. Monopar Therapeutics Inc. has a 52 week low of $29.18 and a 52 week high of $105.00. The firm has a 50 day moving average of $59.89 and a 200 day moving average of $61.79.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. On average, equities research analysts expect that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.